<DOC>
	<DOCNO>NCT00705536</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( PK ) pharmacodynamics ( PD ) Humalog ( insulin lispro ) Humulin-R ( recombinant human insulin ) administer single subcutaneous ( SC ) injection 20 unit ( U ) without coadministration recombinant human hyaluronidase PH20 ( rHuPH20 ) . The study hypothesizes time require reach maximum insulin concentration ( tmax ) insulin administer rHuPH20 comparable short time require without rHuPH20 .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) , Pharmacodynamic ( PD ) , Safety Study Subcutaneously Administered Humalog® With Without Recombinant Human Hyaluronidase ( rHuPH20 ) Humulin-R® With Without rHuPH20</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>1 . Healthy male participant age 18 55 year . 2 . Body mass index ( BMI ) 18 28 kilogram per meter square ( kg/m^2 ) total body weight &gt; 70 kilogram ( kg ) ( 154 pound [ lb ] ) . 3 . Willingness ability comply protocol . 4 . Vital sign within normal range . 5 . Within 7 day first injection , metabolic panel result complete blood count ( CBC ) within laboratory normal reference range . 6 . Fasting plasma glucose within normal range 90 110 milligram per deciliter ( mg/dL ) morning glucose clamp . 7 . Agreement father child donate sperm use effective contraception study least 30 day study completion . 8 . Willingness ability sign inform consent form . 1 . Evidence history clinically significant hematologic , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic ( include history seizure ) allergic disease , history hypoglycemic episode . 2 . Known history diabetes mellitus . 3 . Prior exposure insulin insulin analog . 4 . Known allergy hyaluronidase ingredient HYLENEX . 5 . Known allergy bee vespid venom . 6 . Positive urine drug screen result . 7 . Positive human immunodeficiency virus ( HIV ) 1 , HIV 2 , hepatitis B , hepatitis C antibody test result . 8 . Any history evidence alcohol drug abuse . 9 . History evidence use tobacco nicotinecontaining product within 6 month screen , screen urine nicotine concentration &gt; 50 nanogram per milliliter ( ng/mL ) . 10 . Use prescription nonprescription drug within 7 day 5 halflives , whichever short , except acetaminophen dos less equal 1 gram per day ( g/day ) . 11 . Donation blood excess 500 milliliter ( mL ) within 56 day dose . 12 . Failure limit alcohol consumption refrain exercise within 48 hour injection . 13 . Known clinically significant intercurrent illness major systemic disease would unduly risk participant 's safety interfere interpretation result . 14 . Participation study investigational drug device 30 day enrollment study . 15 . Unfitness study , investigator 's opinion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>rHuPH20</keyword>
	<keyword>Hyaluronidase</keyword>
	<keyword>Insulin</keyword>
</DOC>